Treatment Options: Surgery, Radiation, and Beyond

Deciding how to treat tumor progression after an adrenalectomy is a highly individualized process. Because many of these tumors grow slowly and may not cause symptoms for years, your medical team will weigh the risks of the tumor against the potential side effects of treatment ^[1][2].

Option 1: Careful Observation

If your MRI shows a very small tumor that is not pressing on your optic nerves or other vital structures, observation (often called “watch and wait”) may be appropriate ^[1].

• When it’s used: This is typically reserved for patients with non-compressive lesions and no physical symptoms like vision changes ^[1].
• The Catch: Observation requires a commitment to a strict schedule of “thin-section” MRIs and ACTH blood tests to ensure any growth is caught while the tumor is still easy to treat ^[3].

First-Line Treatment: Transsphenoidal Surgery (TSS)

If the tumor is clearly growing or causing symptoms, transsphenoidal surgery is a common first-line option ^[3]. In this procedure, a neurosurgeon reaches the pituitary gland through the nose, avoiding the need to open the skull.

• Timing is Key: Specialists strongly recommend surgery before the tumor grows out of its “nest” (the sella) and into the surrounding spaces ^[3]. Operating while the tumor is still small increases the chances of a complete and durable remission ^[3].
• Success Rates: In one long-term study cohort, about 80% of patients who had surgery as their primary treatment remained free of further tumor growth for at least 10 years, though outcomes depend heavily on tumor size, invasion, and surgeon experience ^[4].
• Surgical Risks: While generally safe, surgery can cause complications such as a CSF leak (fluid from the brain leaking through the nose), bleeding, visual or vascular injury, or new hormonal deficiencies in about 20-30% of cases, and requires careful perioperative stress-dose steroid planning ^[5][6].

Second-Line Treatment: Radiation and Radiosurgery

If surgery is not possible or if some tumor remains after the operation, radiation is often the next step ^[3]. There are two main types:

1. Stereotactic Radiosurgery (SRS/Gamma Knife): This delivers a single, highly focused dose of radiation directly to the tumor ^[7]. It is very effective at stopping growth, with a local tumor control rate of about 95% in selected cohorts ^[7]. However, it is less effective at lowering ACTH levels quickly; only about 21% of patients see their hormones normalize ^[7].
2. Conventional Radiotherapy: This involves smaller doses of radiation given over several weeks. It is often used if the tumor is too large or too close to the optic nerves for Gamma Knife ^[8].

The Main Risk: The most common delayed side effect of any radiation is partial or complete hypopituitarism (loss of pituitary function) ^[8]. Risk accumulates over the years, and about 20% of patients will develop at least one new hormone deficiency requiring lifelong replacement medications and ongoing visual and endocrine follow-up ^[7].

Third-Line: Medical “Salvage” Therapies

There are currently no medications officially approved by the FDA specifically for Nelson syndrome. However, in aggressive cases where surgery and radiation have failed, doctors may use “off-label” or investigational medications under specialist multidisciplinary care:

• Temozolomide: An oral chemotherapy drug that has shown success in shrinking very aggressive refractory pituitary tumors in some patients, though results are inconsistent ^[9][10].
• Pasireotide: A medication that can significantly lower ACTH levels, though it may not shrink the tumor size for everyone and often requires attention to high blood sugar ^[11][12].
• Cabergoline: Sometimes used to help lower ACTH, though its benefit in Nelson syndrome is generally considered limited ^[13].

These medical options are typically specialist “salvage” therapies, meaning they are used only after standard treatments have been exhausted ^[1].